Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.

Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A.

Am J Obstet Gynecol. 2018 Jun;218(6):624.e1-624.e9. doi: 10.1016/j.ajog.2018.03.001. Epub 2018 Mar 11.

PMID:
29534874
2.

Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.

Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A.

Antimicrob Agents Chemother. 2014 Jun;58(6):3553-5. doi: 10.1128/AAC.02706-13. Epub 2014 Apr 7.

3.

Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis.

Scher RK, Nakamura N, Tavakkol A.

Mycoses. 2014 Jul;57(7):389-93. doi: 10.1111/myc.12168. Epub 2014 Mar 12. Review.

PMID:
24621346
4.

Molecular analysis of dermatophytes suggests spread of infection among household members.

Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A.

Cutis. 2013 May;91(5):237-45.

PMID:
23772429
5.

Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.

Jarratt M, Jones T, Kempers S, Rich P, Morton K, Nakamura N, Tavakkol A.

Cutis. 2013 Apr;91(4):203-10.

PMID:
23763082
6.

Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis.

Jones T, Tavakkol A.

Antimicrob Agents Chemother. 2013 Jun;57(6):2684-9. doi: 10.1128/AAC.02370-12. Epub 2013 Apr 1.

7.

Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens.

Gupta AK, Paquet M, Simpson F, Tavakkol A.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):267-72. doi: 10.1111/j.1468-3083.2012.04584.x. Epub 2012 May 28. Review.

PMID:
22632057
8.

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.

Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A.

Br J Dermatol. 2012 Feb;166(2):389-98. doi: 10.1111/j.1365-2133.2011.10660.x. Epub 2011 Dec 6.

PMID:
21967490
9.

Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.

Krishna G, Ma L, Martinho M, Prasad P, Wahl J, Tavakkol A.

Antimicrob Agents Chemother. 2011 Sep;55(9):4424-6. doi: 10.1128/AAC.01302-10. Epub 2011 Jul 11.

10.

Skin concentrations and pharmacokinetics of posaconazole after oral administration.

Krishna G, Beresford E, Ma L, Vickery D, Martinho M, Yu X, Komjathy S, Tavakkol A.

Antimicrob Agents Chemother. 2010 May;54(5):1807-10. doi: 10.1128/AAC.01616-09. Epub 2010 Mar 1.

11.

Effects of environmentally realistic levels of ozone on stratum corneum function.

He QC, Tavakkol A, Wietecha K, Begum-Gafur R, Ansari SA, Polefka T.

Int J Cosmet Sci. 2006 Oct;28(5):349-57. doi: 10.1111/j.1467-2494.2006.00347.x.

PMID:
18489299
12.

Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials.

Elewski BE, Cáceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, Rachesky IJ, Sanchez-Bal V, Todd G, Wraith L, Cai B, Tavakkol A, Bakshi R, Nyirady J, Friedlander SF.

J Am Acad Dermatol. 2008 Jul;59(1):41-54. doi: 10.1016/j.jaad.2008.02.019. Epub 2008 Apr 18.

PMID:
18378354
13.
14.

Toenail assessment tool for quantitation of visibly infected mycotic nail plate in onychomycosis.

Tavakkol A, Pollak R, Harkless L, Shebetka KA, Weisfeld M, Kianifard F, Jennings M.

Cutis. 2007 Dec;80(6):488-94.

PMID:
18246881
15.

The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis.

Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A.

J Dermatolog Treat. 2007;18(1):46-52.

PMID:
17373090
16.

Onychomycosis: diagnosis and definition of cure.

Scher RK, Tavakkol A, Sigurgeirsson B, Hay RJ, Joseph WS, Tosti A, Fleckman P, Ghannoum M, Armstrong DG, Markinson BC, Elewski BE.

J Am Acad Dermatol. 2007 Jun;56(6):939-44. Epub 2007 Feb 16. Review.

PMID:
17307276
17.

Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial.

Jennings MB, Pollak R, Harkless LB, Kianifard F, Tavakkol A.

J Am Podiatr Med Assoc. 2006 Nov-Dec;96(6):465-73.

PMID:
17114599
18.

Tinea capitis in the United States: Diagnosis, treatment, and costs.

Suh DC, Friedlander SF, Raut M, Chang J, Vo L, Shin HC, Tavakkol A.

J Am Acad Dermatol. 2006 Dec;55(6):1111-2. No abstract available.

PMID:
17110229
19.
21.

Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study.

Kennedy DW, Kuhn FA, Hamilos DL, Zinreich SJ, Butler D, Warsi G, Pfister PJ, Tavakkol A.

Laryngoscope. 2005 Oct;115(10):1793-9.

PMID:
16222197
22.

A comparison of KOH and culture results from two mycology laboratories for the diagnosis of onychomycosis during a randomized, multicenter clinical trial: a subset study.

Arnold B, Kianifard F, Tavakkol A.

J Am Podiatr Med Assoc. 2005 Jul-Aug;95(4):421-3; author reply 423-4. No abstract available.

PMID:
16037563
23.

The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence.

Gupta AK, Ryder JE, Lynch LE, Tavakkol A.

J Drugs Dermatol. 2005 May-Jun;4(3):302-8. Review.

PMID:
15898285
24.

Vitamin E delivery to human skin by a rinse-off product: penetration of alpha-tocopherol versus wash-out effects of skin surface lipids.

Ekanayake-Mudiyanselage S, Tavakkol A, Polefka TG, Nabi Z, Elsner P, Thiele JJ.

Skin Pharmacol Physiol. 2005 Jan-Feb;18(1):20-6.

PMID:
15608499
25.

The use of ozone as an oxidizing agent to evaluate antioxidant activities of natural substrates.

He QC, Krone K, Scherl D, Kotler M, Tavakkol A.

Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):183-9.

PMID:
15258449
26.

Delivery of vitamin E to the skin by a novel liquid skin cleanser: comparison of topical versus oral supplementation.

Tavakkol A, Nabi Z, Soliman N, Polefka TG.

J Cosmet Sci. 2004 Mar-Apr;55(2):177-87.

PMID:
15131729
27.

Bioconversion of vitamin E acetate in human skin.

Nabi Z, Tavakkol A, Dobke M, Polefka TG.

Curr Probl Dermatol. 2001;29:175-86. No abstract available.

PMID:
11225197
28.

Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor.

Tavakkol A, Varani J, Elder JT, Zouboulis CC.

Arch Dermatol Res. 1999 Dec;291(12):643-51.

29.

The effects of prolonged use of surfactants on the skin of normal and photo-exposed hairless mice.

Tavakkol A, Kligman LH, Morrison BM Jr, Polefka TG.

Contact Dermatitis. 1998 Nov;39(5):231-9.

PMID:
9840259
31.

Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation.

Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY, Griffiths CE, Elder JT, et al.

J Invest Dermatol. 1995 Oct;105(4):549-56.

32.

Clinical improvement following dermabrasion of photoaged skin correlates with synthesis of collagen I.

Nelson BR, Majmudar G, Griffiths CE, Gillard MO, Dixon AE, Tavakkol A, Hamilton TA, Woodbury RA, Voorhees JJ, Johnson TM.

Arch Dermatol. 1994 Sep;130(9):1136-42.

PMID:
8085868
33.
35.

Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis.

Fisher GJ, Tavakkol A, Leach K, Burns D, Basta P, Loomis C, Griffiths CE, Cooper KD, Reynolds NJ, Elder JT, et al.

J Invest Dermatol. 1993 Oct;101(4):553-9.

36.

Retinoic acid metabolites exhibit biological activity in human keratinocytes, mouse melanoma cells and hairless mouse skin in vivo.

Reynolds NJ, Fisher GJ, Griffiths CE, Tavakkol A, Talwar HS, Rowse PE, Hamilton TA, Voorhees JJ.

J Pharmacol Exp Ther. 1993 Sep;266(3):1636-42. Erratum in: J Pharmacol Exp Ther 1994 Feb;268(2):1072.

PMID:
8103799
38.

Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin.

Tavakkol A, Elder JT, Griffiths CE, Cooper KD, Talwar H, Fisher GJ, Keane KM, Foltin SK, Voorhees JJ.

J Invest Dermatol. 1992 Sep;99(3):343-9.

39.
40.

Retinoic acid receptors and binding proteins in human skin.

Elder JT, Aström A, Pettersson U, Tavakkol A, Krust A, Kastner P, Chambon P, Voorhees JJ.

J Invest Dermatol. 1992 Jun;98(6 Suppl):36S-41S.

41.

Differential regulation of retinoic acid receptors and binding proteins in human skin.

Elder JT, Aström A, Pettersson U, Tavakkol A, Griffiths CE, Krust A, Kastner P, Chambon P, Voorhees JJ.

J Invest Dermatol. 1992 May;98(5):673-9.

42.

Differential modulation of transforming growth factor-beta 1 expression and mucin deposition by retinoic acid and sodium lauryl sulfate in human skin.

Fisher GJ, Tavakkol A, Griffiths CE, Elder JT, Zhang QY, Finkel L, Danielpour D, Glick AB, Higley H, Ellingsworth L, et al.

J Invest Dermatol. 1992 Jan;98(1):102-8.

43.

Somatic cell mapping and restriction fragment length polymorphism analysis of bovine insulin-like growth factor I.

Bishop MD, Tavakkol A, Threadgill DW, Simmen FA, Simmen RC, Davis ME, Womack JE.

J Anim Sci. 1991 Nov;69(11):4306-11.

PMID:
1684360
46.
47.

Phosphoinositide-mediated signal transduction in normal and psoriatic epidermis.

Fisher GJ, Talwar HS, Tavakkol A, Esmann J, Baldassare JJ, Elder JT, Griffiths CE, Baadsgaard O, Cooper KD, Voorhees JJ.

J Invest Dermatol. 1990 Nov;95(5 Suppl):15S-17S. Review. No abstract available.

48.

Growth factor and proto-oncogene expression in psoriasis.

Elder LT, Klein SB, Tavakkol A, Fisher GJ, Nickoloff BJ, Voorhees JJ.

J Invest Dermatol. 1990 Nov;95(5 Suppl):7S-9S. Review.

49.

Protooncogene expression in normal and psoriatic skin.

Elder JT, Tavakkol A, Klein SB, Zeigler ME, Wicha M, Voorhees JJ.

J Invest Dermatol. 1990 Jan;94(1):19-25.

Supplemental Content

Loading ...
Support Center